• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Investigation on usefulness of Fes / Fer as new therapeutic target and predictive factor in urothelial cancer

Research Project

Project/Area Number 15K10594
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Urology
Research InstitutionNagasaki University

Principal Investigator

TAKEHARA Kosuke  長崎大学, 医歯薬学総合研究科(医学系), 客員研究員 (40580345)

Co-Investigator(Kenkyū-buntansha) 宮田 康好  長崎大学, 医歯薬学総合研究科(医学系), 准教授 (60380888)
望月 保志  長崎大学, 病院(医学系), 准教授 (40404256)
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
KeywordsFes / 尿路癌 / 癌細胞増殖 / 癌細胞浸潤 / 予後 / TUBB3 / 化学療法 / 膀胱癌 / 細胞増殖 / 細胞浸潤 / 細胞遊走 / 遊走能 / Fer / T24
Outline of Final Research Achievements

In T24 cell which is urothelial cancer (UC) cell with high malignant potential, Fes knock-down (KD) lead to significantly suppression of cancer cell proliferation, invasion and migration (P = 0.003, 0.018, and <0.001, respectively). Such significant change by Fes-KD was not detected in 5637 and RT4 cell. In 2013 bladder cancer (BC) patients, there was no significant relationship between Fes expression and muscle invasive status. However, in patients with high grade cancer, Fes expression in muscle invasive BC (MIBC) was significantly higher (P = 0.002) than that in non-MIBC (NMIBC), and its was positively correlated to cell proliferation (P = 0.002). In addition, Fes expression was significantly associated with metastasis-free survival in high grade BC (P = 0.021). On the other hand, class III beta-tubulin (TUBB3), which is Fes/Fer-related molecule, was useful predictor for anti-cancer effects of second-line paclitaxel-based chemotherapy for patients with cisplatin-resistant UC.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • Research Products

    (3 results)

All 2018 2017

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (1 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.2018

    • Author(s)
      Asai A, Miyata Y, Takehara K, Kanda S, Watanabe SI, Greer PA, Sakai H.
    • Journal Title

      Journal of Cancer Research and Clinical Oncology

      Volume: 144 Issue: 1 Pages: 21-31

    • DOI

      10.1007/s00432-017-2524-1

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.2018

    • Author(s)
      Miyata Y, Matsuo T, Nakamura Y, Yasuda T, Ohba K, Takehara K, Sakai H.
    • Journal Title

      Anticancer Research

      Volume: 38 Pages: 1629-1635

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Pathological significance and prognostic roles of FES expression in bladder cancer2017

    • Author(s)
      Akihiro Asai, Yasuyoshi Miyata, Kosuke Takehara, Shigeru Kanda, Shin-ichi Watanabe, Hideki Sakai
    • Organizer
      European Association of Urology, Annual Meeting 2017
    • Place of Presentation
      ロンドン(イギリス)
    • Year and Date
      2017-03-24
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi